

DAFTAR PUSTAKA

- Agur, A. M. R._ Dalley, Arthur F._ Moore, Keith L.-*Essential clinical anatomy-* Wolters Kluwer Health. 2015
- Ankus, E.; Price, S.J.; Ukoumunne, O.C.; Hamilton, W.; Bailey, S.E.R. *Cancer incidence in patients with a high normal platelet count: A cohort study using primary care data.* Fam. Pract. 2018, 35, 671–675. [CrossRef]
- Anna M. Badowska-Kozakiewicz and Michał P. Budzik, *Immunohistochemical characteristics of basal-like breast cancer*, Contemp Oncol (Pozn). 2016; 20(6): 436–443. Published online 2017 Jan 12. doi: 10.5114/wo.2016.56938
- Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, et al. *Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer.* PloS one. 2016; 11(7): e0153459. Epub 2016/07/30. <https://doi.org/10.1371/journal.pone.0153459> PMID: 27472762; PubMed Central PMCID: PMC4966926.
- Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, Habeshy A, Picon A, Bloom S. *Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients.* 2013. Med Oncol 30: 432
- Bailey, S.E., Ukoumunne, O.C., Shephard, E., and Hamilton, W. (2017). *How useful is thrombocytosis in predicting an underlying cancer in primary care? A systematic review.* Fam. Pract. 2017. 34, 4–10.
- Bailey, S.E.R.; Ankus, E.; Price, S.; Pula, G.; Hamilton, W. *The diagnostic potential of high normal platelet counts for identifying cancer in primary care.* Thromb. Res. 2018, 164, S199. [CrossRef]
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.* CA Cancer J Clin. 2018;68(6):394-424.

- Conzen SD, Grushko TA, Olopade OI. *Cancer of the breast. In: Devita Jr VT, editor. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:1415-49.*
- Crandall CJ, Sehl ME, Crawford SL, Gold EB, Habel LA, Butler LM, et al. *Sex steroid metabolism and mammographic density in pre- and early perimenopausal women. Breast Cancer Research. 2009. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19630952>*
- Creighton CJ. *The molecular profile of luminal B breast cancer. Biologics 2012; 6: 289-297 [PMID: 22956860 DOI: 10.2147/BTT.S29923]*
- Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. *Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicentre study. Ann Oncol. 2014. 25: 611–618.*
- Egan K, Crowley D, Smyth P, O’Toole S, Spillane C, Martin C, Gallagher M, Canney A, Norris L, Conlon N, McEvoy L, Ffrench B, Stordal B, Keegan H, Finn S, McEneaney V, Laios A, Ducre´e J, Dunne E, Smith L, Berndt M, Sheils O, Kenny D, O’Leary J. *Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One. 2011. 6: e26125.*
- Faria SS, Fernandes PC, Silva MJB, et al. *The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience, 2016, 10, 702.*
- Goldhirsch A, Winer EP, Coates AS, et al. *Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol. 2013;24(9):2206–2223*
- Gremmel T, Frelinger AL III, Michelson AD. *Platelet physiology. Semin Thromb Hemost. 2016;42(3):191-204.*
- Hashmi AA, Aijaz S, Khan SM, Mahboob R, Irfan M, Zafar NI, et al. *Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. World Journal of Surgical Oncology. 2018; 16:1.*

- Heldin NE, Usuki K, Bergh J, Westermark B, Heldin CH. *Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines*. Br J Cancer. 1993;68(4):708–11. Epub 1993/10/01. pmid:8398697; PubMed Central PMCID: PMC1968610.
- Kono SA, Heasley LE, Doebele RC, Camidge DR. *Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer*. Curr Cancer Drug Targets. 2012. 12: 107–123.
- Krenn-Pilko S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, et al. *The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients*. British journal of cancer. 2014; 110(10):2524–30. <https://doi.org/10.1038/bjc.2014.163> PMID: 24675383; PubMed Central PMCID: PMCPMC4021515.
- Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, Kim HJ. *Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma*. BMC Cancer. 2012. 13: 350.
- Li, Zhi-hua, Hu, Ping-hua, Tu, Jian-hong. *Luminal B breast cancer: Patterns of recurrence and clinical outcome* 2016, DOI - 10.18632/oncotarget.11344
- Ling, G.; Ji, Q.; Ye, W.; Ma, D.; Wang, Y. *Epithelial-mesenchymal transition regulated by p38/MAPK signaling pathways participates in vasculogenic mimicry formation in SHG44 cells transfected with TGF- β cDNA loaded lentivirus in vitro and in vivo*. Int. J. Oncol. 2016, 49, 2387–2398. [CrossRef] [PubMed]
- Liu HL, DU XH, Sun PM, Xiao CH, Xu YX, Li R (2013) *Preoperative plateletlymphocyte ratio is an independent prognostic factor for resectable colorectal cancer*. Nan Fang Yi Ke Da Xue Xue Bao 33: 70–73.
- Llombart-Cussac, A., Cortés, J., Paré, L., Galván, P., Bermejo, B., Martínez, N., Prat, A. *HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-*

- group, multicentre, phase 2 trial*. *The Lancet Oncology*, 2017, 18(4), 545–554. doi:10.1016/s1470-2045(17)30021-9
- Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, Piccart MJ, Speed TP, McArthur GA. *Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer*. *BMC Med Genomics* 2009; 2: 37 [PMID: 19552798 DOI: 10.1186/1755-8794-2-37]
- Martin AM, Cagney DN, Catalano PJ, et al. *Brain metastases in newly diagnosed breast cancer: a population-based study*. *JAMA Oncol*. 2017;3(8):1069–1077. [PMC free article] [PubMed] [Google Scholar]
- Notoatmodjo S. *Metodologi Penelitian Kesehatan*. Jakarta: 2010, PT. Rineka Cipta.
- Ozlem Yersal, Süleyman Çetinküner, Recep Aktimur, Mehmet Aziret, Sabri Özdaş Hasan Erdem, Kadir Yildirim, *Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios are Not Different among Breast Cancer Subtypes, 2017*, *Asian Pac J Cancer Prev*, 18 (8), 2227-2231
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslén LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. *Molecular portraits of human breast tumours*. *Nature* 2000; 406:747-752. (PMID: 10963602) [CrossRef]
- Qiu AF1, Miao ZL, Ge GK, Wang CB, Bian J, Ma HY, Xu Q. *Response and prognosis of neoadjuvant dose-dense or standard schedule chemotherapy with anthracyclines and taxanes for Luminal B breast cancer*. *Zhonghua Yi Xue Za Zhi*. 2017 Nov 28;97(44):3466-3470. doi: 10.3760/cma.j.issn.0376-2491.2017.44.006.
- Rafee S, McHugh D, Grealley M, Ayodele O, Keegan N, Lim M, et al. *Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as predictive biomarkers of pathologic complete response (pCR) in neoadjuvant breast cancer: an Irish Clinical Oncology Group study (ICORG 16–20)*. *Annals of Oncology*. 2016; 27(suppl 6):1538P.

- Raunkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. *Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer*. J Gynecol Oncol. 2012, 23: 265–273.
- Ring A, Smith I, Ashley S, Fulford L, Lakhani S. *Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer*. Br J Cancer. 2004;91(12):2012–2017
- Seretis C, Seretis F, Lagoudianakis E, Politou M, Gemenetzi G, Salemis NS. *Enhancing the accuracy of platelet to lymphocyte ratio after adjustment for large platelet count: a pilot study in breast cancer patients*. Int J Surg Oncol. 2012; 2012:653608. <https://doi.org/10.1155/2012/653608> PMID: 23304480; PubMed Central PMCID: PMC3532869.
- Siegel RL, Miller KD, Jemal A. *Cancer statistics, 2016*. CA Cancer J Clin 2016;66:7-30.
- Suzuki K, Aiura K, Ueda M, Kitajima M. *The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents*. Pancreas 2004 29: 132–140.
- Takeuchi H, Fukuyama S, Kubo N, Hiroshige S, Kawanaka H, Yoshikawa Y, et al. *The prognostic significance of the preoperative platelet-lymphocyte ratio in Japanese patients with localized breast cancer*. Adv Breast Cancer Res. 2016; 5: 49±57.
- Wen, S.; Hou, Y.; Fu, L.; Xi, L.; Yang, D.; Zhao, M.; Qin, Y.; Sun, K.; Teng, Y.; Liu, M. *Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β 3-p38 MAPK signalling*. Cancer Lett. 2019, 442, 320–332. [CrossRef] [PubMed]
- West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. *Tumor-infiltrating lymphocytes predict response to anthracyclinebased chemotherapy in estrogen receptor-negative breast cancer*. Breast Cancer Res 2011, 13: R126.

- Widodo I, Dwianingsih EK, Triningsih E, Utoro T, Soeripto. *Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes*. Asian Pac J Cancer Prev. 2014;15:6109-13.
- Yersal O, Barutca S. *Biological subtypes of breast cancer: Prognostic and therapeutic implications*. World J Clin Oncol 2014; 5(3): 412-424 Available from: URL: <http://www.wjgnet.com/2218-4333/full/v5/i3/412.htm> DOI: <http://dx.doi.org/10.5306/wjco.v5.i3.412>
- Yerushalmi R, Kennecke H, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. *Metastatic behavior of breast cancer subtypes*. J Clin Oncol 2010; 28: 3271-3277. (PMID: 20498394) [CrossRef]
- Zuo XX, Yang Y, Zhang Y, Zhang ZG, Wang XF, Shi YG, *Platelets promote breast cancer cell MCF-7 metastasis by direct interaction: surface integrin $\alpha 2\beta 1$ -contacting-mediated activation of Wnt- β -catenin pathway*. 2019. Cell Communication and Signaling : CCS, 07 Nov 2019, 17(1):142